NCT04788745View on ClinicalTrials.gov

Targeting Metabolic Flexibility in Amyotrophic Lateral Sclerosis (ALS)

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

June 29, 2021

Primary Completion Date

May 24, 2023

Study Completion Date

May 24, 2023

Conditions
Amyotrophic Lateral SclerosisMotor Neuron Disease
Interventions
DRUG

Trimetazidine Dihydrochloride

Oral tablet, twice-daily

Trial Locations (3)

4029

Royal Brisbane & Women's Hospital, Brisbane

Unknown

University Medical Centre Utrecht, Utrecht

King's College London, London

Sponsors

Collaborators (1)

Julius Clinical
All Listed Sponsors
collaborator

FightMND

OTHER

collaborator

UMC Utrecht

OTHER

collaborator

King's College London

OTHER

collaborator

Julius Clinical

INDUSTRY

lead

The University of Queensland

OTHER

NCT04788745 - Targeting Metabolic Flexibility in Amyotrophic Lateral Sclerosis (ALS) | Biotech Hunter | Biotech Hunter